skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The epidermal growth factor receptor family in breast cancer

Review

(2868) Views  (707) Full article downloads

Authors: Angelos K Koutras, T R Jeffry Evans

Published Date September 2008 Volume 2008:1 Pages 5 - 19
DOI: http://dx.doi.org/10.2147/OTT.S3842

Angelos K Koutras1, T R Jeffry Evans2

1Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom; 2University of Glasgow, Cancer Research UK Beatson Laboratories, Garscube Estate, Switchback Road, Glasgow G61 1BD, United Kingdom

Abstract: The human epidermal growth factor receptor (HER) family comprises four homologous members: EGFR, HER-2, HER-3, and HER-4. The activation of these receptors triggers a complex series of signal transduction pathways which affect pivotal tumorigenic processes. The deregulation of HER signaling is seen in several human malignancies. HER-2 is now recognized as a key oncogene in breast cancer pathogenesis. Assessment of HER-2 status is of central importance in the prognosis of breast cancer patients. In the light of clinical data suggesting that HER-2 can also be useful as a predictive marker both for trastuzumab and chemotherapy, standardized determination of the HER-2 status in tumors has become more important. Moreover, current data provide evidence for the significance of HER-3 and HER-4 alterations in breast carcinogenesis. Because of the complex interactions among the HER receptors, it is likely that the effect on cell proliferation and tumor growth depends on receptor trans-signaling and thus, the evaluation of the combined expression pattern of all family members is of particular interest. This review presents the current evidence highlighting the role of the family as a whole panel and an update on the role of HER-3 and HER-4 receptors in breast cancer. Moreover, we provide updated data regarding the prognostic value of HER family members giving emphasis to novel methods for the determination of their status, such as real-time polymerase chain reaction. In addition, we review recent therapeutic approaches aimed at targeting the HER family in breast cancer patients.

Keywords: epidermal growth factor, receptor, breast cancer








Readers of this article also read:

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
Targeted treatment of advanced and metastatic breast cancer with lapatinib
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
Rational use of cetuximab in the treatment of advanced non-small cell lung cancer
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Bendamustine in the treatment of non-Hodgkin’s lymphomas
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
Primary care for diabetes mellitus: perspective from older patients